Rifadin is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Sanofi-aventis U.s. Llc. The primary component is Rifampin.
| Product ID | 0068-0508_10a42985-61e0-4145-92ee-703871e7312a |
| NDC | 0068-0508 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Rifadin |
| Generic Name | Rifampin |
| Dosage Form | Capsule |
| Route of Administration | ORAL |
| Marketing Start Date | 1971-05-21 |
| Marketing End Date | 2020-10-31 |
| Marketing Category | NDA / NDA |
| Application Number | NDA050420 |
| Labeler Name | Sanofi-Aventis U.S. LLC |
| Substance Name | RIFAMPIN |
| Active Ingredient Strength | 300 mg/1 |
| Pharm Classes | Rifamycin Antibacterial [EPC],Rifamycins [CS] |
| NDC Exclude Flag | N |
| Marketing Start Date | 1971-05-21 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA050420 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 1971-05-21 |
| Marketing End Date | 2017-07-31 |
| Marketing Category | NDA |
| Application Number | NDA050420 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 1971-05-21 |
| Marketing Category | NDA |
| Application Number | NDA050420 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1971-05-21 |
| Marketing End Date | 2013-04-15 |
| Ingredient | Strength |
|---|---|
| RIFAMPIN | 300 mg/1 |
| SPL SET ID: | 036ab68e-5085-4edc-bd83-784b43d64eab |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0068-0508 | Rifadin | rifampin |
| 0068-0510 | Rifadin | rifampin |
| 0068-0597 | Rifadin IV | rifampin |
| 0068-0599 | Rifadin IV NOVAPLUS | rifampin |
| 0143-9230 | Rifampin | Rifampin |
| 0185-0799 | Rifampin | Rifampin |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() RIFADIN 72314539 0879813 Live/Registered |
DOW CHEMICAL COMPANY, THE 1968-12-16 |